Induction and Therapeutic Targeting of Human NPM1c+ Myeloid Leukemia in the Presence of Autologous Immune System in Mice Mandeep Kaur, Adam C. Drake, Guangan Hu, Stephen Rudnick, Qingfeng Chen, Ryan Phennicie, Ricardo Attar, Jeffrey Nemeth, Francois Gaudet, Jianzhu Chen The Journal of Immunology March 15, 2019, 202 (6) 1885-1894; DOI: 10.4049/jimmunol.1800366
Abstract:
Development of targeted cancer therapy requires a thorough understanding of mechanisms of tumorigenesis as well as mechanisms of action of therapeutics. This is challenging because by the time patients are diagnosed with cancer, early events of tumorigenesis have already taken place. Similarly, development of cancer immunotherapies is hampered by a lack of appropriate small animal models with autologous human tumor and immune system. In this article, we report the development of a mouse model of human acute myeloid leukemia (AML) with autologous immune system for studying early events of human leukemogenesis and testing the efficacy of immunotherapeutics. To develop such a model, human hematopoietic stem/progenitor cells (HSPC) are transduced with lentiviruses expressing a mutated form of nucleophosmin (NPM1), referred to as NPM1c. Following engraftment into immunodeficient mice, transduced HSPCs give rise to human myeloid leukemia, whereas untransduced HSPCs give rise to human immune cells in the same mice. The de novo AML, with CD123+ leukemic stem or initiating cells (LSC), resembles NPM1c+ AML from patients. Transcriptional analysis of LSC and leukemic cells confirms similarity of the de novo leukemia generated in mice with patient leukemia and suggests Myc as a co-operating factor in NPM1c-driven leukemogenesis. We show that a bispecific conjugate that binds both CD3 and CD123 eliminates CD123+ LSCs in a T cell–dependent manner both in vivo and in vitro. These results demonstrate the utility of the NPM1c+ AML model with an autologous immune system for studying early events of human leukemogenesis and for evaluating efficacy and mechanism of immunotherapeutics.
License type:
Funding Info:
This work was supported in part by a TRANSCEND grant from Janssen Pharmaceuticals, Inc., the Ivan R. Cottrell Professorship and Research Fund, and Koch Institute Support (Core) Grant P30-CA14051 from the National Cancer Institute.
Description:
The full paper is available for download at the publisher's URL: https://doi.org/10.4049/jimmunol.1800366